Fennec Pharmaceuticals (FENC) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed Fennec Pharmaceuticals (FENC) over the past year, gaining 54.2% versus a gain of 21.1%. Over five years, FENC leads with a +13.9% price change compared with -87.0% for RLMD. Fennec Pharmaceuticals is the larger company by market cap ($350.0 million vs $330.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FENC | RLMD |
|---|---|---|
| Share price | $9.98 | $3.10 |
| Market cap | $349.97M | $330.68M |
| 1-day change | -3.57% | -3.13% |
| YTD return | +29.61% | -35.82% |
| 1-year return | +21.12% | +54.23% |
| 5-year return | +13.93% | -86.99% |
| Forward P/E | 10.53 | — |
| EPS (TTM) | $-0.12 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.64M | — |
| Revenue growth (YoY) | -6.09% | — |
| Net income (latest FY) | $-9.74M | $-57.39M |
| Operating margin | -14.07% | — |
| Net margin | -21.82% | — |
| 52-week high | $13.25 | $8.00 |
| 52-week low | $5.65 | $1.97 |
| Distance from 52-week high | -24.68% | -61.25% |
| Analyst consensus | none | none |
| Avg. price target upside | +77.05% | +246.77% |
| Average volume | 188.89K | 1.30M |
| Shares outstanding | 35.07M | 106.67M |
| Employees | 35 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLMD has outperformed FENC by 33.1 percentage points over the past year.
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Healthcare · Biotechnology · 35 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Healthcare · Biotechnology · 17 employees
FENC vs RLMD FAQ
Which is bigger, Fennec Pharmaceuticals or Relmada Therapeutics?
Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $349.97M compared with $330.68M for Relmada Therapeutics (RLMD).
Which stock has performed better over the past year, FENC or RLMD?
RLMD returned +54.23% over the past 12 months, compared with +21.12% for FENC (price return, excluding dividends). Past performance does not predict future results.
Are Fennec Pharmaceuticals and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.